Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality.
Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality.
Forge Biologics was founded in 2020 by Tim Miller, Jaysson Eicholtz and Erandi De Silva. The company is headquartered in Columbus, Ohio.
Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an AAV to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
Forge is backed by RA Capital Management, Drive Capital, Perceptive Xontogeny Venture Fund, State of Ohio, Surveyor Capital, Octagon Capital, and others. The company raised $90M in a Series C round on Sep 12, 2022. This brings Forge's total funding to $330M to date.